期刊
CANCERS
卷 13, 期 14, 页码 -出版社
MDPI
DOI: 10.3390/cancers13143507
关键词
real world; biliary tract neoplasms; gemcitabine; oxaliplatin; palliative care; chemotherapy
类别
资金
- FORSS grants [FORSS-941207]
- Region Ostergotland ALF grants [RO-937640, RO-935580, RO-798701]
- CKOC
This study evaluated the real-world outcomes of GemOx treatment in 121 patients with advanced biliary tract cancer in three hospitals in the South East Region of Sweden. The median overall survival was 8.9 months, with prognostic factors including performance status and primary gallbladder carcinoma. Most patients received a lower dose of oxaliplatin than previous studies suggested, which appeared to be more tolerable.
Simple Summary Cancers of the biliary tract are rare but severe with high mortality rates. Randomised controlled trials suggest that chemotherapies such as gemcitabine and oxaliplatin (GemOx) may relieve symptoms and prolong life, but less is known on the efficacy and safety of such regimens in real life. The current paper assessed the real-world outcome of GemOx in all patients with advanced biliary tract cancer treated at any cancer centre in the South East Region of Sweden over a period of nine years. The median overall survival was nine months and time to disease progression five months. Prognostic factors such as performance status and gall bladder (rather than bile duct) localisation of the primary tumour were identified. Most patients received a lower dose of oxaliplatin than proposed by previous studies, which seemed feasible as few patients had severe adverse events. This study supports further use of GemOx as standard of care. Background: Gemcitabine and oxaliplatin (GemOx) is a standard combination regimen in advanced biliary tract cancer (BTC). There is limited evidence on its efficacy and safety in real life. Methods: A retrospective multicentre cohort study in the South East Region of Sweden, covering nine years (2011-2020) and three hospitals where GemOx was treatment of choice, was designed. Clinicopathological prognostic parameters were explored. Results: One hundred and twenty-one patients with advanced BTC were identified. Median overall and progression-free survival (OS and PFS) were 8.9 (95% CI = 7.2-10.6) and 5.3 (95% CI = 3.8-6.7) months. Performance status according to Eastern Cooperative Oncology Group (PS according to ECOG) 1-2 and primary gallbladder carcinoma were independent predictors for poor OS. PS and derived neutrophil/lymphocyte ratio were predictive for PFS. The most common severe type of myelosuppresion was grade 3 neutropenia that was recorded in 8%. Fifty-three (43.8%) experienced at least one episode of unplanned hospitalisation. One hundred and seventeen (97%) received oxaliplatin with lower dosage than was utilized in previous phase III trials (80-85 vs. 100 mg/m(2)) and a majority received further dose reductions of oxaliplatin and/or gemcitabine. Conclusion: The outcome of GemOx in advanced BTC appears comparable in controlled trials and real-world contexts. A lower dose of oxaliplatin seems more tolerable without compromising the outcome.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据